Germany's BaFin looking into possible insider trading of CureVac shares
BERLIN (Reuters) - German financial watchdog BaFin is investigating possible insider trading of vaccine maker’s CureVac shares, which fell after the biotech firm announced its COVID-19 vaccine proved only 47% effective, Rheinische Post newspaper reported on Monday.
BaFin will investigate whether employees at Curevac or Bayer could have used their insider knowledge of the vaccine study results and sold shares in good time, the newspaper added.
Shares in CureVac droped more than 50% on Thursday following the company’s announcement, erasing more than 6 billion euros ($7.2 billion) from the company’s market value.
A BaFin spokesperson declined to comment on individual cases but said the authority examines unusual price movements to determine whether there is any suspicion of market abuse or manipulation.
CureVac was not immediately available to comment on the report.
Reporting by Riham Alkousaa and Hans Seidenstuecker; Editing by Paul Carrel